For instance, cancer preventatives, like tamoxifen for estrogen receptor-positive (ER+) breast cancers, have shown clinical efficacy; yet, the prevention of ER- breast cancers, including the erbB-2-overexpressing subtype, remains elusive [1, 2]. Here, ERBB2 is linked to breast cancer.